TM6SF2 and metabolic dysfunction-associated steatohepatitis: Further, the clarification of the detailed mechanisms of action (e.g., loss-of-function studies for Tm6sf2) is expected to add more details prior to the application of Mdivi-1 as a therapeutic agent for NASH.